WHO consolidated guidelines on tuberculosis 2020 moving toward fully oral regimen: Should country act in hurry?
作者信息
Jain Nirmal Kumar
机构信息
Department of Respiratory Medicine, JNU Medical College, Jaipur, Rajasthan, India.
出版信息
Lung India. 2021 Jul-Aug;38(4):303-306. doi: 10.4103/lungindia.lungindia_982_20.
Abstract
摘要
相似文献
1
WHO consolidated guidelines on tuberculosis 2020 moving toward fully oral regimen: Should country act in hurry?《世界卫生组织2020年结核病综合指南：迈向全口服治疗方案》：各国应匆忙行动吗？
Lung India. 2021 Jul-Aug;38(4):303-306. doi: 10.4103/lungindia.lungindia_982_20.
3
Effectiveness and safety of fully oral modified shorter treatment regimen for multidrug-resistant tuberculosis in Georgia, 2019-2020.2019-2020 年格鲁吉亚多药耐药结核病全口服改良短程治疗方案的有效性和安全性。
Monaldi Arch Chest Dis. 2021 Jan 14;91(1). doi: 10.4081/monaldi.2021.1679.
4
Impact of the change from an injectable to a fully oral regimen on patient adherence to ambulatory tuberculosis treatment in Dar es Salaam, Tanzania.从注射疗法改为完全口服疗法对坦桑尼亚达累斯萨拉姆市门诊肺结核治疗患者依从性的影响。
Tuber Lung Dis. 1995 Aug;76(4):286-9. doi: 10.1016/s0962-8479(05)80025-5.
7
[Human rights of patients and tuberculosis prevention].[患者的人权与结核病预防]
Kekkaku. 2008 Feb;83(2):111-4.
9
World Health Organization 2018 treatment guidelines for rifampicin-resistant tuberculosis: uncertainty, potential risks and the way forward.世界卫生组织 2018 年利福平耐药结核病治疗指南：不确定性、潜在风险和前进方向。
Int J Antimicrob Agents. 2020 Jan;55(1):105822. doi: 10.1016/j.ijantimicag.2019.10.003. Epub 2019 Oct 15.
10
[Interpretation of WHO consolidated guidelines on tuberculosis module 4: drug resistant tuberculosis treatment].[世界卫生组织结核病综合指南模块4：耐多药结核病治疗解读]
Zhonghua Jie He He Hu Xi Za Zhi. 2021 Apr 12;44(4):349-353. doi: 10.3760/cma.j.cn112147-20200709-00786.
引用本文的文献
1
Newer research transforming 24-month treatment of MDR/XDR-TB TO 6 months.最新研究将耐多药/广泛耐药结核病的24个月治疗转变为6个月治疗。
Lung India. 2025 Mar 1;42(2):140-146. doi: 10.4103/lungindia.lungindia_431_24. Epub 2025 Feb 27.
2
Reply: Roll out of bedaquiline without drug susceptibility testing leads to emergence of bedaquiline-resistance in high burden countries with tuberculosis - Danger of losing a novel drug.回复：在未进行药敏试验的情况下推广使用贝达喹啉会导致结核病高负担国家出现贝达喹啉耐药性——失去一种新药的风险。
Lung India. 2022 Jul-Aug;39(4):389-390. doi: 10.4103/lungindia.lungindia_31_22.
3
India should speed up access to bedaquiline-based all-oral regimens, not procrastinate further.印度应加快获取以贝达喹啉为基础的全口服治疗方案，而不是进一步拖延。
Lung India. 2021 Nov-Dec;38(6):590-591. doi: 10.4103/lungindia.lungindia_425_21.
本文引用的文献
1
Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis.药物相关不良事件在耐多药结核病治疗中的作用：一项个体患者数据荟萃分析。
Lancet Respir Med. 2020 Apr;8(4):383-394. doi: 10.1016/S2213-2600(20)30047-3. Epub 2020 Mar 17.
2
Management of multidrug-resistant tuberculosis with shorter treatment regimen in Niger: Nationwide programmatic achievements.尼日内陆缩短耐多药结核病治疗方案的管理：全国规划成果。
Respir Med. 2020 Jan;161:105844. doi: 10.1016/j.rmed.2019.105844. Epub 2019 Nov 23.
3
Short-Course Regimen for Multidrug-Resistant Tuberculosis: A Decade of Evidence.耐多药结核病的短程治疗方案：十年证据
J Clin Med. 2019 Dec 25;9(1):55. doi: 10.3390/jcm9010055.
4
Multidrug-resistant tuberculosis.耐多药结核病
Lancet. 2019 Jul 27;394(10195):299. doi: 10.1016/S0140-6736(19)30046-7.
5
A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis.一项针对耐利福平结核病的较短疗程的试验。
N Engl J Med. 2019 Mar 28;380(13):1201-1213. doi: 10.1056/NEJMoa1811867. Epub 2019 Mar 13.
6
Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.德拉马尼联合优化背景治疗方案治疗耐多药结核病的疗效和安全性：一项多中心、随机、双盲、安慰剂对照、平行分组 3 期临床试验。
Lancet Respir Med. 2019 Mar;7(3):249-259. doi: 10.1016/S2213-2600(18)30426-0. Epub 2019 Jan 7.
7
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.肺耐多药结核病成功治疗结果的相关因素：一项个体患者数据荟萃分析。
Lancet. 2018 Sep 8;392(10150):821-834. doi: 10.1016/S0140-6736(18)31644-1.
8
Improved Treatment Outcomes With Bedaquiline When Substituted for Second-line Injectable Agents in Multidrug-resistant Tuberculosis: A Retrospective Cohort Study.贝达喹啉替代二线注射剂治疗耐多药结核病的疗效改善：一项回顾性队列研究。
Clin Infect Dis. 2019 Apr 24;68(9):1522-1529. doi: 10.1093/cid/ciy727.
9
Principles for constructing a tuberculosis treatment regimen: the role and definition of core and companion drugs.构建结核病治疗方案的原则：核心药物和辅助药物的作用和定义。
Int J Tuberc Lung Dis. 2018 Mar 1;22(3):239-245. doi: 10.5588/ijtld.17.0660.
10
Safety and efficacy of exposure to bedaquiline-delamanid in multidrug-resistant tuberculosis: a case series from France and Latvia.使用贝达喹啉-地拉马尼治疗耐多药结核病的安全性和有效性：来自法国和拉脱维亚的病例系列
Eur Respir J. 2018 Mar 22;51(3). doi: 10.1183/13993003.02550-2017. Print 2018 Mar.
Zotero 插件